Anteris Technologies Global Corp. is a structural heart company engaged in discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. It is engaged in the research and development of its biomimetic technology (ADAPT, DurAVR Transcatheter Heart Valve (THV), ComASUR Transfemoral Delivery System) to address unmet medical needs in the treatment of aortic stenosis. The DurAVR THV, with its single piece, native-shaped biomimetic design is built to mimic the performance of a healthy aortic valve and to restore normal laminar (smooth) blood flow. This class of technology can be used to treat new aortic stenosis patients and to treat aortic stenosis patients with failed valves (valve-in-valve). ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. ComASUR is its balloon-expandable delivery system.
企業コードAVR
会社名Anteris Technologies Global Corp
上場日Dec 13, 2024
最高経営責任者「CEO」Mr. Wayne G. Paterson
従業員数136
証券種類Ordinary Share
決算期末Dec 13
本社所在地860 Blue Gentian Road
都市EAGAN
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号55121
電話番号16514930606
ウェブサイトhttps://anteristech.com/
企業コードAVR
上場日Dec 13, 2024
最高経営責任者「CEO」Mr. Wayne G. Paterson
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし